The Effect of Doxycycline on Matrix Metalloproteinase Expression and Activity in the Abdominal Aneurysm

This study has been completed.
Information provided by:
Leiden University Medical Center Identifier:
First received: October 2, 2007
Last updated: NA
Last verified: October 2007
History: No changes posted
The matrix metalloproteinase-9 (MMP-9) is considered to play a central role in abdominal aortic aneurysm (AAA) initiation. Doxycycline has direct MMP-9 inhibiting properties in vitro, and it effectively suppresses AAA development in rodents. Observed inhibition of AAA progression, and contradictory findings in human studies evaluating the effect of doxycycline therapy on aortic wall MMP-9 suggest that the effects of doxycycline extend beyond MMP-9 inhibition, and that the effect may be dose dependent.

Condition Intervention Phase
Aortic Aneurysm, Abdominal
Drug: doxycycline
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Basic Science
Official Title: The Effect of Doxycycline on Matrix Metalloproteinase Expression and Activity in the Abdominal Aneurysm

Resource links provided by NLM:

Further study details as provided by Leiden University Medical Center:

Primary Outcome Measures:
  • Collagenase mRNA and protein expression [ Time Frame: 2 weeks ]

Enrollment: 60
Study Start Date: May 2002
Study Completion Date: August 2005
Arms Assigned Interventions
No Intervention: 1
Active Comparator: 2
doxycycline 50 mg/day
Drug: doxycycline
2 weeks once daily
Active Comparator: 3
doxycycline 100 mg
Drug: doxycycline
2 weeks once daily
Active Comparator: 4
doxycycline 300 mg
Drug: doxycycline
2 weeks once daily

Detailed Description:
In this clinical trial, we evaluated the effect of two weeks of low (50 mg/day), medium (100 mg/day) or high dose (300 mg/day) doxycycline versus no medication in patients undergoing elective AAA repair. The effect of doxycycline treatment on MMP and cysteine proteases, and their respective inhibitors was evaluated in an integrative approach.

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Elective open aneurysm repair

Exclusion Criteria:

  • Severe kidney and liver dysfunction
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00538967

Leiden University Medical Center
Leiden, Netherlands, 2300RC
Sponsors and Collaborators
Leiden University Medical Center
Principal Investigator: Jan HN Lindeman, MD, PhD Leiden University Medical Center
  More Information Identifier: NCT00538967     History of Changes
Other Study ID Numbers: P00.146 
Study First Received: October 2, 2007
Last Updated: October 2, 2007
Health Authority: Netherlands: Medical Ethics Review Committee (METC)

Keywords provided by Leiden University Medical Center:

Additional relevant MeSH terms:
Aortic Aneurysm
Aortic Aneurysm, Abdominal
Aortic Diseases
Cardiovascular Diseases
Vascular Diseases
Anti-Bacterial Agents
Anti-Infective Agents
Antiparasitic Agents
Antiprotozoal Agents
Pharmacologic Actions
Therapeutic Uses processed this record on April 27, 2016